Efficacy of sequential cyclical hormonal therapy in endometrial cancer and its correlation with steroid hormone receptor status

Ayoub, Jean-Pierre M.; Audet-Lapointe, P; Méthot, Y; Hanley, James A.; Beaulieu, Raymond; Chemaly, R.; Cormier, André; Déry, J.P.; Drouin, Pascal; Gauthier, Philippe; Guay, JP; Husson, David; Labrie, Fernand; Lambert, B.; Latreille, Jean; Mandeville, Rosemonde; Michon, Bruno; Pichet, R.; Sidrac, S.

doi:10.1016/0020-7292(89)90637-1

Cited by 4 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a randomized trial of a combination chemotherapy regimen, adriamycin was given to all patients, who were then randomized to presence or absence of progesterone in the treatment regimen (28). The addition of progesterone was associated with a statistically significant improvement in cancer tissue specimens (28). In this context, it may be appropriate to speculate that endometrial cancers that express SLC22A16 have the potential to adapt to the combination therapy including adriamycin and progesterone.…”

Section: Discussionmentioning

confidence: 98%

“…The expression status of SLC22A16 and PR in endometrial cancer tissues and these information might predict responsibility of the combination treatment of hormone therapy with progesterone and chemotherapy including adriamycin. In a randomized trial of a combination chemotherapy regimen, adriamycin was given to all patients, who were then randomized to presence or absence of progesterone in the treatment regimen (28). The addition of progesterone was associated with a statistically significant improvement in cancer tissue specimens (28).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Expression of Organic Cation Transporter SLC22A16 in Human Endometria

Sato

Itō

Onogawa

et al. 2007

International Journal of Gynecological Pathology

View full text Add to dashboard Cite

SLC22A16 is one of newly isolated organic cation transporters, which is responsible for uptake and transport of adriamycin into cells. Adriamycin is one of the key drugs for treatment of endometrial cancer. Therefore, we examined expression of SLC22A16 in human endometrium and its disorders. Protein and mRNA expression levels of SLC22A16 were examined in 124 endometrial cancer specimens, 25 normal endometrial tissue samples (15 in proliferative phase, 10 in secretory phase), and 7 endometrial cancer cell lines using immunohistochemical analysis and reverse transcription-polymerase chain reaction. Changes in SLC22A16 mRNA expression level after progesterone exposure were also examined. Immunohistochemical analysis showed that SLC22A16 protein was highly expressed in endometrium during the normal secretory phase, but its level was significantly reduced in the proliferative phase. SLC22A16 protein was detected in 59 of 124 (48%) endometrial cancer specimens and 3 of 7 (43%) endometrial cancer cell lines. The mRNA levels measured by quantitative reverse transcription-polymerase chain reaction were comparable with levels of protein expression. Furthermore, SLC22A16 mRNA levels were increased in endometrial cancer cell lines in the presence of progesterone. In conclusion, SLC22A16 is expressed in various endometrial tissues. Its expression level is high during the secretory phase and may be regulated by progesterone. Our findings also suggest that it may be possible to use progestins to increase the response of endometrioid endometrial carcinoma with SLC22A16 expression to adriamycin-based chemotherapeutic regimens.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Expression of Organic Cation Transporter SLC22A16 in Human Endometria

Sato

Itō

Onogawa

et al. 2007

International Journal of Gynecological Pathology

View full text Add to dashboard Cite

show abstract

“…In vitro, mRNA expression of OCT6 by endometrial cancer cells is increased in response to progesterone [80]. Improved response rates to cyclophosphamide/doxorubicin/5-fluorouracil chemotherapy with the addition of medroxyprogesterone may be due to increased expression of doxorubicin transporter OCT6 by endometrial cancers [82].…”

Section: Organic Cation Transportersmentioning

confidence: 99%

Overview of SLC22A and SLCO Families of Drug Uptake Transporters in the Context of Cancer Treatments

Cutler

Choo²

2011

CDM

View full text Add to dashboard Cite

The effectiveness of many anticancer agents is dependent on their disposition to the intracellular space of cancerous tissue. Accumulation of anticancer drugs at their sites of action can be altered by both uptake and efflux transport proteins, however the majority of research on the disposition of anticancer drugs has focused on drug efflux transporters and their ability to confer multidrug resistance. Here we review the roles of uptake transporters of the SLC22A and SLCO families in the context of cancer therapy. The many first-line anticancer drugs that are substrates of organic cation transporters (OCTs) organic cation/carnitine transporters (OCTNs) and organic anion- transporting polypeptides (OATPs) are summarized. In addition, where data is available a comparison of the localization of drug uptake transporters in healthy and cancerous tissues is provided. Expression of drug uptake transporters increases the sensitivity of cancer cell lines to anticancer substrates. Furthermore, early observational studies have suggested a causal link between drug uptake transporter expression and positive outcome in some cancers. Quantification of drug transporters by mass spectrometry will provide an essential technique for generation of expression data during future observational clinical studies. Screening of drug uptake transporter expression in primary tumors may help differentiate between susceptible and resistant cancers prior to therapy.

show abstract

“…Responses range between 15% and 74%, but the limited data available do not show an improvement in survival. 39,40 Currently, there appears to be no evidence in support of concurrent chemotherapy and hormonal treatment of EC.…”

Section: Chemotherapymentioning

confidence: 99%

Advances in the treatment of endometrial cancer

Oehler

Fung

Jobling

2005

British Menopause Society Journal

View full text Add to dashboard Cite

Endometrial cancer (EC) most commonly affects postmenopausal women. It is curable if treated early, but tumours with adverse histopathological features or at an advanced stage are associated with a high mortality rate. These cancers require a complex therapeutic approach, consisting of surgery, radiotherapy, chemotherapy and/or hormonal therapy. As one of the leading causes of death from malignancy in women, EC has been subject to intense clinical investigation. This article examines recent advances in the surgical treatment of the disease, such as sentinel lymph node sampling and total laparoscopic hysterectomy, as well as topics such as conservative treatment of EC for fertility preservation. Furthermore, new agents for EC treatment are presented, for example inhibitors of the mTOR pathway and the angiogenesis-inhibitor VEGF-trap.

show abstract

Efficacy of sequential cyclical hormonal therapy in endometrial cancer and its correlation with steroid hormone receptor status

Cited by 4 publications

References 0 publications

Expression of Organic Cation Transporter SLC22A16 in Human Endometria

Expression of Organic Cation Transporter SLC22A16 in Human Endometria

Overview of SLC22A and SLCO Families of Drug Uptake Transporters in the Context of Cancer Treatments

Advances in the treatment of endometrial cancer

Contact Info

Product

Resources

About